Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.220
Filter
Add more filters

Publication year range
1.
Proc Natl Acad Sci U S A ; 117(1): 573-583, 2020 01 07.
Article in English | MEDLINE | ID: mdl-31852820

ABSTRACT

Fuchs endothelial corneal dystrophy (FECD) is a leading cause of corneal endothelial (CE) degeneration resulting in impaired visual acuity. It is a genetically complex and age-related disorder, with higher incidence in females. In this study, we established a nongenetic FECD animal model based on the physiologic outcome of CE susceptibility to oxidative stress by demonstrating that corneal exposure to ultraviolet A (UVA) recapitulates the morphological and molecular changes of FECD. Targeted irradiation of mouse corneas with UVA induced reactive oxygen species (ROS) production in the aqueous humor, and caused greater CE cell loss, including loss of ZO-1 junctional contacts and corneal edema, in female than male mice, characteristic of late-onset FECD. UVA irradiation caused greater mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) damage in female mice, indicative of the sex-driven differential response of the CE to UVA, thus accounting for more severe phenotype in females. The sex-dependent effect of UVA was driven by the activation of estrogen-metabolizing enzyme CYP1B1 and formation of reactive estrogen metabolites and estrogen-DNA adducts in female but not male mice. Supplementation of N-acetylcysteine (NAC), a scavenger of reactive oxygen species (ROS), diminished the morphological and molecular changes induced by UVA in vivo. This study investigates the molecular mechanisms of environmental factors in FECD pathogenesis and demonstrates a strong link between UVA-induced estrogen metabolism and increased susceptibility of females for FECD development.


Subject(s)
Cytochrome P-450 CYP1B1/metabolism , DNA Adducts/radiation effects , DNA Damage/radiation effects , Estrogens/metabolism , Fuchs' Endothelial Dystrophy/etiology , Ultraviolet Rays/adverse effects , Acetylcysteine/administration & dosage , Animals , Aqueous Humor/drug effects , Aqueous Humor/metabolism , Aqueous Humor/radiation effects , DNA Adducts/metabolism , DNA Damage/drug effects , DNA, Mitochondrial/metabolism , DNA, Mitochondrial/radiation effects , Disease Models, Animal , Endothelium, Corneal/drug effects , Endothelium, Corneal/pathology , Endothelium, Corneal/radiation effects , Female , Free Radical Scavengers/administration & dosage , Fuchs' Endothelial Dystrophy/diagnosis , Fuchs' Endothelial Dystrophy/drug therapy , Fuchs' Endothelial Dystrophy/pathology , Humans , Male , Mice , Oxidative Stress/radiation effects , Reactive Oxygen Species/metabolism , Severity of Illness Index
2.
Pharm Biol ; 60(1): 225-234, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35068295

ABSTRACT

CONTEXT: Cordyceps militaris and Isaria tenuipes (Cordycipitaceae) are high-value fungi that are used for health-promoting food supplements. Since laboratory cultivation has begun for these fungi, increased output has been achieved. OBJECTIVE: This study compared the chemical profiles, antioxidant, anti-tyrosinase, and skin extracellular matrix degradation inhibition between mycelium and fruiting body of C. militaris and I. tenuipes. MATERIALS AND METHODS: The antioxidative potential of 10% v/v aqueous infused extract from each fungus was separately investigated using 2,2-azinobis(3-ethylbenzo-thiazoline-6-sulphonic acid) (ABTS), 1,1-diphenyl-2-picrylhydrazyl (DPPH), ferric reducing antioxidant ability, and ferric thiocyanate methods. The inhibition against MMP-1, elastase, and hyaluronidase were determined to reveal their anti-wrinkle potential. Anti-tyrosinase activities were determined. RESULTS: C. militaris and I. tenuipes extracts were found to contain a wide range of bioactive compounds, including phenolics, flavonoids, and adenosine. A correlation was discovered between the chemical compositions and their biological activities. The extract from I. tenuipes fruiting body (IF) was highlighted as an extraordinary elastase inhibitor (IC50 = 0.006 ± 0.004 mg/mL), hyaluronidase inhibitor (IC50: 30.3 ± 3.2 mg/mL), and antioxidant via radical scavenging (ABTS IC50: 0.22 ± 0.02 mg/mL; DPPH IC50: 0.05 ± 0.02 mg/mL), thereby reducing ability (EC1: 95.3 ± 4.8 mM FeSO4/g extract) and lipid peroxidation prevention (IC50: 0.40 ± 0.11 mg/mL). IF had a three-times higher EC1 value than ascorbic acid and significantly higher elastase inhibition than epigallocatechin gallate. DISCUSSION AND CONCLUSIONS: IF is proposed as a powerful natural extract with antioxidant and anti-wrinkle properties; therefore, it is suggested for further use in pharmaceutical, cosmeceutical, and nutraceutical industries.


Subject(s)
Antioxidants/pharmacology , Cordyceps/chemistry , Enzyme Inhibitors/pharmacology , Monophenol Monooxygenase/antagonists & inhibitors , Animals , Antioxidants/administration & dosage , Antioxidants/isolation & purification , Ascorbic Acid/pharmacology , Catechin/analogs & derivatives , Catechin/pharmacology , Cattle , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/isolation & purification , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/isolation & purification , Free Radical Scavengers/pharmacology , Fruiting Bodies, Fungal , Inhibitory Concentration 50 , Mycelium , Skin/drug effects , Skin/metabolism , Skin Aging/drug effects , Swine
3.
BMC Plant Biol ; 21(1): 180, 2021 Apr 15.
Article in English | MEDLINE | ID: mdl-33858330

ABSTRACT

BACKGROUND: Melatonin, a multifunctional signal molecule, has been reported to play crucial roles in growth and development and stress responses in various plant species. Okra (Abelmoschus esculentus L.) is a food crop with extremely high values of nutrition and healthcare. Recent reports have revealed the protective role of melatonin in alleviating salt stress. However, little is known about its regulatory mechanisms in response to salt stress in okra. RESULTS: In this study, we explored whether exogenous melatonin pretreatment could alleviate salt stress (300 mM NaCl) of okra plants. Results showed that exogenous application of melatonin (50 µM) significantly enhanced plant tolerance to salt stress, as demonstrated by the plant resistant phenotype, as well as by the higher levels of the net photosynthetic rate, chlorophyll fluorescence and chlorophyll content in comparison with nontreated salt-stressed plants. Additionally, melatonin pretreatment remarkably decreased the levels of lipid peroxidation and H2O2 content and scavenged O2•- in melatonin-pretreated plants, which may be attributed to the higher levels of enzyme activities including POD and GR. Moreover, a combination of third- (PacBio) and second-generation (Illumina) sequencing technologies was applied to sequence full-length transcriptomes of okra. A total of 121,360 unigenes was obtained, and the size of transcript lengths ranged from 500 to 6000 bp. Illumina RNA-seq analysis showed that: Comparing with control, 1776, 1063 and 1074 differential expression genes (DEGs) were identified from the three treatments (NaCl, MT50 and MT + NaCl, respectively). These genes were enriched in more than 10 GO terms and 34 KEGG pathways. Nitrogen metabolism, sulfur metabolism, and alanine, aspartate and glutamate metabolism were significantly enriched in all three treatments. Many transcription factors including MYB, WRKY, NAC etc., were also identified as DEGs. CONCLUSIONS: Our preliminary results suggested that melatonin pretreatment enhanced salt tolerance of okra plants for the first time. These data provide the first set of full-length isoforms in okra and more comprehensive insights into the molecular mechanism of melatonin responses to salt stress.


Subject(s)
Abelmoschus/physiology , Melatonin/administration & dosage , Salt Tolerance , Transcriptome , Abelmoschus/drug effects , Abelmoschus/genetics , Antioxidants/administration & dosage , Free Radical Scavengers/administration & dosage , Gene Expression Profiling , Salt Tolerance/drug effects
4.
Surg Today ; 51(11): 1860-1871, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33787966

ABSTRACT

PURPOSE: Acute peritonitis has remained a fatal disease despite of recent advances in care and treatment, including antibiotic and anticoagulant treatments. The cause of death is mostly sepsis-induced multiple organ failure. Oxidative stress can play an important role in this situation, but antioxidant therapy to capture any excessive reactive oxygen species has not yet been fully established. METHODS: Two experiments were performed. In the first experiment, we confirmed the effects of peritoneal lavage with hydrogen-rich saline (HRS) after a cecal ligation and puncture (CLP) operation in rats. In the second experiment, the changes in the hemodynamic state following this procedure were observed in a porcine model of abdominal sepsis to evaluate its safety and utility. RESULTS: Peritoneal lavage with HRS significantly improved the survival after CLP in rats, and it ameliorated the levels of sepsis-induced organ failure. Moreover, it showed anti-inflammatory and anti-apoptosis as well as antioxidant effects. The second experiment demonstrated the potential safety and feasibility of this procedure in a large animal model. CONCLUSION: This procedure can improve survival after sepsis through mitigating the sepsis-induced organ failure by inhibiting oxidative stress, apoptosis, and inflammatory pathways. Peritoneal lavage with HRS may therefore be an effective, safe, and practical therapy for patients with acute peritonitis.


Subject(s)
Antioxidants/administration & dosage , Free Radical Scavengers/administration & dosage , Hydrogen/administration & dosage , Peritoneal Lavage/methods , Peritonitis/therapy , Saline Solution/administration & dosage , Sepsis/therapy , Acute Disease , Animals , Disease Models, Animal , Male , Oxidative Stress , Peritonitis/etiology , Rats, Inbred F344 , Reactive Oxygen Species , Sepsis/etiology , Treatment Outcome
5.
Arch Gynecol Obstet ; 303(4): 1009-1016, 2021 04.
Article in English | MEDLINE | ID: mdl-33201374

ABSTRACT

PURPOSE: We aimed to evaluate the protective effect of edaravone on radiation-induced ovarian damage in an experimental rat model. METHODS: Thirty-two Wistar albino female rats were randomly divided into four groups. Group 1: control, no treatment, and radiation was applied throughout the study; Group 2: sham, only radiation was applied; Group 3: 45 mg/kg edaravone and radiation were applied; Group 4: 450 mg/kg edaravone and radiation were applied. Edaravone was administered intraperitoneally 30 min before radiotherapy (5 Gy). Two days after radiation exposure, the rats were sacrificed and the ovaries were removed. Histologic changes under light microscopy and immunoreactivity for anti-caspase-3 were noted and compared between the four groups. RESULTS: There was a statistically significant difference in follicle counts, vascular congestion, edema, cytoplasmic vacuolization, hemorrhage, and interstitial cell degeneration between the groups. Radiation causes deterioration in most histopathological parameters. Administration of edaravone at different doses seems to reverse these alterations and alleviate the injury. Antioxidant defense mechanisms appear to be enhanced by edaravone as shown by histopathologically and decreased apoptosis by reducing the expression of anti-caspase-3 activity as demonstrated immunohistochemically. CONCLUSION: This is the first study evaluating the protective effects of edaravone on radiation-induced ovarian damage. Edaravone decreased the follicular apoptosis and attenuates the radiation-induced ovarian damage in rats.


Subject(s)
Edaravone/therapeutic use , Free Radical Scavengers/therapeutic use , Ovary/radiation effects , Radiation Injuries/prevention & control , Reperfusion Injury/prevention & control , Animals , Disease Models, Animal , Edaravone/administration & dosage , Female , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/pharmacology , Ovary/pathology , Rats , Rats, Wistar , Reperfusion Injury/pathology
6.
Drug Chem Toxicol ; 44(4): 437-446, 2021 Jul.
Article in English | MEDLINE | ID: mdl-31064223

ABSTRACT

Cisplatin has been widely used as an anticancer agent for a wide range of tumors, but it had nephrotoxicity that was mainly caused by oxidative stress. Edaravone, a free radical scavenger, has reportedly been validated to have a protective effect against renal injury induced by reactive oxygen species. However, most of these reports are against AKI, and few studies have examined the effect of chronic renal injury. In this study, we investigate the effect of edaravone on cisplatin nephropathy in the chronic phase. Twenty-five male Wistar rats were divided into five groups: control, cisplatin, cisplatin + edaravone 1 mg kg-1, cisplatin + edaravone 10 mg kg-1, and cisplatin + edaravone 100 mg kg-1. Edaravone was administrated intraperitoneally every other day for 5 weeks, starting 1 week before cisplatin administration (6 mg kg-1, i.p.). As a result, proximal tubule injury, interstitial fibrosis, and mononuclear cell infiltration were ameliorated histologically in the group of rats treated with high edaravone dose. In the cisplatin group, the number of α-SMA-, CD68-, and CD3-positive cells increased markedly compared with the Control group, but these numbers were significantly decreased by higher doses of co-administered edaravone. While there was no clear mRNA expression variation in antioxidant enzymes, the apoptosis-promoting factors, caspase8, were markedly reduced in the high-dose edaravone co-administration group compared with the cisplatin group. In conclusion, our results suggested that cisplatin-induced renal injury in the chronic phase was ameliorated by edaravone.


Subject(s)
Cisplatin/toxicity , Edaravone/pharmacology , Kidney Diseases/chemically induced , Oxidative Stress/drug effects , Animals , Antineoplastic Agents/toxicity , Antioxidants/metabolism , Caspase 8/metabolism , Dose-Response Relationship, Drug , Edaravone/administration & dosage , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/pharmacology , Kidney Diseases/prevention & control , Male , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism
7.
Drug Chem Toxicol ; 44(4): 341-352, 2021 Jul.
Article in English | MEDLINE | ID: mdl-30907158

ABSTRACT

Chronic exposure to toxic inorganic arsenic results in the adverse health effects including skin lesions, cardiovascular diseases, diabetes, neurological disorders, and liver and kidney diseases. Gallic acid (GA) is an important phenolic compound, which could protect different tissues from oxidative stress induced damage. The present study investigated effects of GA against sodium arsenite (SA)-induced renal and hepatic toxicity. Thirty-five rats were randomly divided in to five groups; group 1 was treated with normal saline (2 ml/kg/day, p.o.; for 21 days); group 2 was exposed to SA (10 mg/kg/day, p.o.; for 14 days); groups 3 and 4 were treated with GA (10 and 30 mg/kg/day, respectively; for 7 days) prior to exposure to SA, and treatment was continued up to 21 days in parallel with SA administration; group 5 was treated with GA (30 mg/kg/day, p.o.; for 21 days). The level of MDA, IL-1ß, NO and glutathione (GSH) and the activity of glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) were evaluated in kidney and liver tissues. Histopathological parameters and serum levels of ALT, AST, ALP, Cr and BUN were also assessed. Treatment with GA remarkably improved SA-induced alteration of hematological and histopathological parameters; these protective effects were associated with the reduction of SA-induced elevation of MDA, IL-1ß and NO levels as well as reduction of GSH level and GPx, SOD and CAT activity. Our results suggest that GA may inhibit SA-induced kidney and liver toxicity through scavenging reactive free radicals and increasing intracellular antioxidant capacity.


Subject(s)
Arsenites/toxicity , Chemical and Drug Induced Liver Injury/prevention & control , Gallic Acid/pharmacology , Kidney Diseases/prevention & control , Sodium Compounds/toxicity , Animals , Antioxidants/metabolism , Catalase/metabolism , Chemical and Drug Induced Liver Injury/etiology , Dose-Response Relationship, Drug , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/pharmacology , Gallic Acid/administration & dosage , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Kidney Diseases/chemically induced , Male , Oxidative Stress/drug effects , Rats , Rats, Wistar , Superoxide Dismutase/metabolism
8.
Drug Dev Res ; 82(2): 207-216, 2021 04.
Article in English | MEDLINE | ID: mdl-32897587

ABSTRACT

A series of new heterocycles (4-18) was synthesized by the structural modification of benzimidazole-2-thiol (BT, 2-MBI). The structures of the synthesized compounds were confirmed with the help of high-resolution mass spectrometry (HRMS) and 1 HNMR spectroscopy. High inhibitions of the oxidants such as ABTS and DPPH were observed for compounds 9 [IC50 (s) = 167.4 µM (ABTS), 139.5 µM (DPPH)], 10 [IC50 (s) = 186.5 µM (ABTS), 155.4 µM (DPPH)], 11 [IC50 (s) = 286.1 µM (ABTS), 189.1 µM (DPPH)], 12 [IC50 (s) = 310.8 µM (ABTS), 162.2 µM (DPPH)], 14 [IC50 (s) = 281.3 µM (ABTS), 205.7 µM (DPPH)], 15 [IC50 (s) = 284.1 µM (ABTS), 177.3 µM (DPPH)], and 16 [IC50 (s) = 344.7 µM (ABTS), 270.2 µM (DPPH)] as compared with Ascorbic acid [IC50 (s) = 340.9 µM (ABTS), 164.3 µM (DPPH)]. The anti-Alzheimer's activity was performed in vitro against cholinesterase enzymes (AChE, BChE). Compound 11 was able to show significant inhibitions [IC50 (s) = 121.2 µM (AChE), 38.3 µM (BChE)] as against that of galantamine [IC50 (s) = 139.4 µM (AChE), 40.3 µM (BChE)]. Compound 14 was found as a very good inhibitor of butyrylcholinesterase (IC50 = 35.4 µM) as compared with standard galantamine. Molecular docking was further performed to investigate the mechanism of anticholinesterase activity.


Subject(s)
Alzheimer Disease/drug therapy , Benzimidazoles/administration & dosage , Chemistry, Pharmaceutical/methods , Drug Delivery Systems/methods , Free Radical Scavengers/administration & dosage , Sulfhydryl Compounds/administration & dosage , Benzimidazoles/chemical synthesis , Free Radical Scavengers/chemical synthesis , Humans , Molecular Docking Simulation/methods , Protein Structure, Secondary , Sulfhydryl Compounds/chemical synthesis
9.
Int Heart J ; 62(1): 142-147, 2021 Jan 30.
Article in English | MEDLINE | ID: mdl-33390565

ABSTRACT

The aim of this study was to evaluate the clinical efficacy of N-acetylcysteine (NAC) in the treatment of ST segment elevation myocardial infarction (STEMI).PubMed, EMBASE, Cochrane Library, and Web of Science were searched systematically from the establishment of the database to June 2020. Two researchers independently completed literature screening and data extraction and conducted a meta-analysis.Nine articles including 1419 patients were enrolled. Meta-analysis showed that all-cause mortality [RR = 0.56, 95%CI (0.33, 0.93), P = 0.02], occurrence of major adverse cardiovascular events (MACE) [RR = 0.63, 95%CI (0.47, 0.85), P = 0.002], and myocardial enzyme hs-TnT level [SMD = -0.42, 95%CI (-0.71, -0.13), P = 0.005] were significantly lower in patients with STEMI treated with NAC than those in the control group. There was no significant difference between the NAC group and the control group in new congestive heart failure [RR = 0.94, 95%CI (0.48, 1.82), P = 0.84], ejection fraction [MD = 2.00, 95%CI (-0.59, 4.60), P = 0.13], and CK-MB [SMD = -0.18, 95%CI (-0.47, 0.11), P = 0.23]. There was no significant difference in the occurrence of adverse reactions between the NAC group and the control group [RR = 1.04, 95%CI (0.57-1.89), P = 0.90].NAC can reduce the all-cause mortality and MACE cases of STEMI.


Subject(s)
Acetylcysteine/therapeutic use , Free Radical Scavengers/therapeutic use , Myocardial Infarction/drug therapy , ST Elevation Myocardial Infarction/drug therapy , Acetylcysteine/administration & dosage , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/mortality , Cardiovascular Diseases/prevention & control , Case-Control Studies , Creatine Kinase, MB Form/metabolism , Female , Free Radical Scavengers/administration & dosage , Heart Failure/mortality , Heart Failure/physiopathology , Heart Failure/prevention & control , Humans , Male , Middle Aged , Myocardial Infarction/metabolism , Myocardial Infarction/mortality , Myocardial Infarction/physiopathology , Percutaneous Coronary Intervention/methods , Randomized Controlled Trials as Topic , ST Elevation Myocardial Infarction/mortality , Stroke Volume , Treatment Outcome , Troponin T/metabolism
10.
Molecules ; 26(6)2021 Mar 18.
Article in English | MEDLINE | ID: mdl-33803643

ABSTRACT

Unprotected exposure of skin to solar ultraviolet radiation (UVR) may damage the DNA of skin cells and can lead to skin cancer. Sunscreens are topical formulations used to protect skin against UVR. The active ingredients of sunscreens are UV filters that absorb, scatter, and/or reflect UVR. Preventing the formation of free radicals and repairing DNA damages, natural antioxidants are also added to sunscreens as a second fold of protection against UVR. Antioxidants can help stabilise these formulations during the manufacturing process and upon application on skin. However, UV filters and antioxidants are both susceptible to degradation upon exposure to sunlight and oxygen. Additionally, due to their poor water solubility, natural antioxidants are challenging to formulate and exhibit limited penetration and bioavailability in the site of action (i.e., deeper skin layers). Cyclodextrins (CDs) are cyclic oligosaccharides that are capable of forming inclusion complexes with poorly soluble drugs, such as antioxidants. In this review, we discuss the use of CDs inclusion complexes to enhance the aqueous solubility of antioxidants and chemical UV filters and provide a protective shield against degradative factors. The role of CDs in providing a controlled drug release profile from sunscreens is also discussed. Finally, incorporating CDs inclusion complexes into sunscreens has the potential to increase their efficiency and hence improve their skin cancer prevention.


Subject(s)
Cyclodextrins/pharmacology , Skin Neoplasms/prevention & control , Sunscreening Agents/pharmacology , Antioxidants/administration & dosage , Antioxidants/chemistry , Antioxidants/pharmacology , Cyclodextrins/administration & dosage , Cyclodextrins/chemistry , DNA Damage , Delayed-Action Preparations , Drug Compounding , Drug Stability , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/chemistry , Free Radical Scavengers/pharmacology , Humans , Molecular Structure , Skin/drug effects , Skin/metabolism , Skin/radiation effects , Solubility , Sunscreening Agents/administration & dosage , Sunscreening Agents/chemistry , Ultraviolet Rays/adverse effects
11.
AAPS PharmSciTech ; 22(5): 167, 2021 Jun 02.
Article in English | MEDLINE | ID: mdl-34080078

ABSTRACT

In developing countries, populations have employed herbal medicines for primary health care because they are believed to be more appropriate to the human body and have less side effects than chemically synthesized drugs. The present study aimed to develop and evaluate herbal tablets incorporated with a Thai traditional medicinal extract, U-pa-ri-waat (URW), using microwave-assisted extraction (MAE). The extraction efficiency for URW using MAE and traditional solvent extraction was compared based on the percent yield after spray drying. URW tablets were prepared using the dry granulation method. The optimized products were assessed using standard characterization methods based on the United States and British Pharmacopeias. DPPH and ABTS radical scavenging assays were performed to analyze the antioxidant capacity of the microwave-assisted extracts. The results revealed that the flowability of the dry granule with added maltodextrin was improved compared to a granule without additives, as indicated by an angle of repose of 33.69 ± 2.0°, a compressibility index of 15.38 ± 0.66, and a Hausner's ratio of 1.18 ± 0.06. The resulting formulation produced flat tablets with uniform weight variation, hardness, thickness, friability, and optimum disintegration time. The URW extracts showed antioxidant activity and MAE with maltodextrin carrier displayed the strongest DPPH and ABTS radical activities with IC50 values of 1.60 ± 0.02 µg/mL and 4.02 ± 0.24 µg/mL, respectively. The URW tablet formulation passed the quality control tests. Storage of the formulation tablets for 90 days under accelerated conditions had minimal effects on tablet characteristics.


Subject(s)
Chemistry, Pharmaceutical/methods , Microwaves , Phytochemicals/chemical synthesis , Plant Preparations/chemical synthesis , Administration, Oral , Antioxidants/administration & dosage , Antioxidants/chemical synthesis , Antioxidants/pharmacokinetics , Drug Evaluation, Preclinical/methods , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/chemical synthesis , Free Radical Scavengers/pharmacokinetics , Herbal Medicine/methods , Humans , Phytochemicals/administration & dosage , Phytochemicals/pharmacokinetics , Plant Preparations/administration & dosage , Plant Preparations/pharmacokinetics , Tablets , Thailand
12.
Pharm Biol ; 59(1): 504-512, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33905670

ABSTRACT

CONTEXT: Gynura bicolour (Roxb. and Willd.) DC (Asteraceae) leaf is a common vegetable. Ethanol extracts of fresh G. bicolour leaves (GBEE) have several physiological effects, but studies on atherosclerosis are limited. OBJECTIVE: We investigated the oxidant scavenging ability and vascular adhesion molecule expression of these extracts. MATERIALS AND METHODS: The antioxidant effects of 0.05-0.4 mg/mL GBEE were analyzed in vitro. Intracellular antioxidant capacity and adhesion molecule levels were detected in EA.hy926 cells pre-treated with 10-100 µg/mL GBEE for 8 h, then TNF-α for 3 h. The antioxidant capacity of red blood cells and the adhesion molecule levels in the thoracic aorta were detected in high-fat diet (HFD)-fed Sprague-Dawley rats treated with GBEE for 12 weeks. RESULTS: The in vitro EC50 values of GBEE based on its DPPH radical-scavenging ability, reducing power, and ferrous ion-chelating ability were 0.20, 3.21 and 0.49 mg/mL, respectively. In TNF-α-treated EA.hy926 cells, the thiobarbituric acid-reactive substance levels were decreased after 10, 50, or 100 µg/mL GBEE treatments (IC50: 19.1 mg/mL). When HFD-fed rats were co-treated with GBEE, the GBEE-H group exhibited 25% higher glutathione levels than the HFD group (p < 0.05). E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion protein-1 levels were decreased in TNF-α-treated EA.hy926 cells after GBEE treatment (by approximately 11-73%; p < 0.05), and the above three adhesion molecules levels were decreased in HFD-fed rats with combined GBEE treatment (by approximately 30-77%; p < 0.05). CONCLUSIONS: GBEE can protect the vascular endothelium by reducing adhesion molecule expression and regulating antioxidants. It may have the potential to prevent atherosclerosis.


Subject(s)
Antioxidants/metabolism , Asteraceae/chemistry , Atherosclerosis/prevention & control , Plant Extracts/pharmacology , Animals , Aorta, Thoracic/drug effects , Diet, High-Fat , Disease Models, Animal , Dose-Response Relationship, Drug , E-Selectin/metabolism , Endothelium, Vascular/drug effects , Ethanol/chemistry , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/isolation & purification , Free Radical Scavengers/pharmacology , Inhibitory Concentration 50 , Intercellular Adhesion Molecule-1/metabolism , Male , Plant Extracts/administration & dosage , Rats , Rats, Sprague-Dawley , Vascular Cell Adhesion Molecule-1/metabolism
13.
Am J Kidney Dis ; 75(2): 187-194, 2020 02.
Article in English | MEDLINE | ID: mdl-31547939

ABSTRACT

RATIONALE & OBJECTIVE: The PRESERVE trial used a 2 × 2 factorial design to compare intravenous saline solution with intravenous sodium bicarbonate solution and oral N-acetylcysteine with placebo for the prevention of 90-day major adverse kidney events and death (MAKE-D) and contrast-associated acute kidney injury (CA-AKI) among patients with chronic kidney disease undergoing angiography. In this ancillary study, we evaluated the predictive capacities of preangiography injury and repair proteins in urine and plasma for MAKE-D, CA-AKI, and their impact on trial design. STUDY DESIGN: Longitudinal analysis. SETTING & PARTICIPANTS: A subset of participants from the PRESERVE trial. EXPOSURES: Injury (KIM-1, NGAL, and IL-18) and repair (MCP-1, UMOD, and YKL-40) proteins in urine and plasma 1 to 2 hours preangiography. OUTCOMES: MAKE-D and CA-AKI. ANALYTICAL APPROACH: We analyzed the associations of preangiography biomarkers with MAKE-D and with CA-AKI. We evaluated whether the biomarker levels could enrich the MAKE-D event rate and improve future clinical trial efficiency through an online biomarker prognostic enrichment tool available at prognosticenrichment.com. RESULTS: We measured plasma biomarkers in 916 participants and urine biomarkers in 797 participants. After adjusting for urinary albumin-creatinine ratio and baseline estimated glomerular filtration rate, preangiography levels of 4 plasma (KIM-1, NGAL, UMOD, and YKL-40) and 3 urine (NGAL, IL-18, and YKL-40) biomarkers were associated with MAKE-D. Only plasma KIM-1 level was significantly associated with CA-AKI after adjustment. Biomarker levels provided modest discriminatory capacity for MAKE-D. Screening patients using the 50th percentile of preangiography plasma KIM-1 or YKL-40 levels would have reduced the required sample size by 30% (∼2,000 participants). LIMITATIONS: Evaluation of prognostic enrichment does not account for changing trial costs, time needed to screen patients, or loss to follow-up. Most participants were male, limiting the generalizability of our findings. CONCLUSIONS: Preangiography levels of injury and repair biomarkers modestly predict the development of MAKE-D and can be used to improve the efficiency of future CA-AKI trials.


Subject(s)
Acetylcysteine/administration & dosage , Acute Kidney Injury/metabolism , Acute-Phase Proteins/metabolism , Angiography/adverse effects , Contrast Media/adverse effects , Cytokines/metabolism , Sodium Bicarbonate/administration & dosage , Acute Kidney Injury/chemically induced , Acute Kidney Injury/drug therapy , Administration, Oral , Aged , Biomarkers/blood , Biomarkers/urine , Female , Follow-Up Studies , Free Radical Scavengers/administration & dosage , Glomerular Filtration Rate , Humans , Infusions, Intravenous , Kidney Function Tests , Male , Prognosis
14.
Hepatology ; 69(2): 774-784, 2019 02.
Article in English | MEDLINE | ID: mdl-30125376

ABSTRACT

Historically, intravenous acetylcysteine has been delivered at a fixed dose and duration of 300 mg/kg over 20 to 21 hours to nearly every patient deemed to be at any risk for hepatotoxicity following acetaminophen overdose. We investigated a 12-hour treatment regimen for selected low-risk patients. This was a multicenter, open-label, cluster-controlled trial at six metropolitan emergency departments. We enrolled subjects following single or staggered acetaminophen overdose with normal serum alanine transaminase (ALT) and creatinine on presentation and at 12 hours, and less than 20 mg/L acetaminophen at 12 hours. Patients were allocated to intervention (250 mg/kg over 12-hour) or control (300 mg/kg over 20-hour) regimens by site. The primary outcome was incidence of "hepatic injury" 20 hours following initiation of acetylcysteine treatment, defined as ALT doubling and peak ALT greater than 100 IU/L, indicating the need for further antidotal treatment. Secondary outcomes included incidence of hepatotoxicity (ALT > 1,000 IU/L), peak international normalized ratio (INR), and adverse drug reactions. Of the 449 acetaminophen overdoses receiving acetylcysteine, 100 were recruited to the study. Time to acetylcysteine (median 7 hours [interquartile ratio 6,12] versus 7 hours [6,10]) and initial acetaminophen (124 mg/L [58,171] versus 146 mg/L [66,204]) were similar between intervention and control groups. There was no difference in ALT (18 IU/L [13,22] versus 16 IU/L [13,21]) or INR (1.2 versus 1.2) 20 hours after starting acetylcysteine between groups. No patients developed hepatic injury or hepatotoxicity in either group (odds ratio 1.0 [95% confidence interval 0.02, 50]). No patients represented with liver injury, none died, and 96 of 96 were well at 14-day telephone follow-up. Conclusion: Discontinuing acetylcysteine based on laboratory testing after 12 hours of treatment is feasible and likely safe in selected patients at very low risk of liver injury from acetaminophen overdose.


Subject(s)
Acetaminophen/poisoning , Acetylcysteine/administration & dosage , Chemical and Drug Induced Liver Injury/drug therapy , Free Radical Scavengers/administration & dosage , Acetaminophen/blood , Adolescent , Adult , Alanine Transaminase/blood , Chemical and Drug Induced Liver Injury/blood , Creatinine/blood , Feasibility Studies , Female , Humans , Male , Young Adult
15.
Pediatr Transplant ; 24(7): e13792, 2020 11.
Article in English | MEDLINE | ID: mdl-32881212

ABSTRACT

Data on pediatric patients with HPS undergoing LT are limited. Our aim was to study the spectrum and outcomes of pediatric patients with HPS undergoing LDLT. The role ofiNO for post-LDLT refractory hypoxemia was also assessed. Patients (aged < 18 years) undergoing LT were retrospectively studied. HPS was diagnosed based on European Respiratory Society Taskforce 2004 criteria. HPS was graded based on oxygenation criteria and contrast-enhanced echocardiogram. Post-operative course was studied. Refractory post-operative hypoxemia was treated with iNO by institutionally developed protocol. 23/150 pediatric patients undergoing LDLT had HPS. BA was the most common underlying cause (52.2%). By oxygenation criteria, 6 (26.1%) had VS-HPS. VS-HPS was associated with longer LOS (p = .031) and prolonged oxygen requirement (p = .001) compared with other HPS patients. 4/6 patients with VS-HPS had pO2 < 45 mm Hg. Among these, 2 developed ICH post-operatively and 1 died. 3 developed refractory post-operative hypoxemia, successfully treated with iNO. Mean duration of iNO was 26.3 days. In the group of patients with HPS, the incidence of HAT and portal vein thrombosis was 17.3% and 4.3%, respectively. One year post-LDLT survival of patients with HPS was similar to non-HPS patients (86.9% vs 94.4%; p = .88). We concluded that, pediatric patients with VS-HPS, especially those with pre-operative pO2 < 45 mm Hg, have long and difficult post-LT course. Refractory postoperative hypoxemia can be successfully overcome with strategic use of iNO. Vigilant monitoring and good intensive care support are essential.


Subject(s)
Hepatopulmonary Syndrome/surgery , Hypoxia/drug therapy , Liver Transplantation/adverse effects , Nitric Oxide/administration & dosage , Postoperative Complications/drug therapy , Administration, Inhalation , Adolescent , Child , Child, Preschool , Follow-Up Studies , Free Radical Scavengers/administration & dosage , Graft Survival , Hepatopulmonary Syndrome/diagnosis , Humans , Hypoxia/etiology , Infant , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome
16.
Dig Dis Sci ; 65(12): 3726-3733, 2020 12.
Article in English | MEDLINE | ID: mdl-32072435

ABSTRACT

INTRODUCTION: In this study, we assessed whether there were any survival advantages with a combination treatment of intravenous N-acetylcysteine (NAC) and prednisone over prednisone alone in those with severe alcoholic hepatitis [discriminant function (DF) ≥ 32]. PATIENTS AND METHODS: Between January 1, 2013, and February 28, 2019, we identified 68 patients (mean age 47.2 years ± 10.1, 57% women, 65% cirrhosis, MELD score 28.1 ± 6.6) with alcoholic hepatitis, and of those, 21 (31%) received prednisone and 47 (69%) received prednisone + NAC. Lille score ≥ 0.45 was considered a poor response. Renal insufficiency was defined as GFR < 60 ml/min/1.73m2 calculated on two separate occasions. RESULTS: DF (74.2 ± 33.6 vs. 56.9 ± 15.9, p = 0.09) was similar, but MELD (29.2 ± 6.3 vs. 25.5 ± 6.4, p = 0.03) scores were higher in the combination group. The overall 30-day and 90-day mortality was 13.2% (9/68) and 20.6% (14/68), respectively. Women were more likely (OR 4.86, 95% CI 1.62-14.59) to respond to treatment based on Lille score compared to men, but the type of treatment regimen had no effect on Lille score (OR 0.84, 95% CI 0.25-2.78). Treatment regimen had no effect on both adjusted and unadjusted survivals. Multivariate analysis, after adjusting for confounding variables, confirmed these observations. DF + renal insufficiency had the highest AUROC (0.86) to predict mortality. CONCLUSION: The combination treatment of NAC + prednisone is not better than prednisone alone in patients with severe alcoholic hepatitis.


Subject(s)
Acetylcysteine , Hepatitis, Alcoholic , Liver Cirrhosis , Prednisone , Acetylcysteine/administration & dosage , Acetylcysteine/adverse effects , Adult , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Drug Monitoring/methods , Drug Therapy, Combination/methods , Female , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/adverse effects , Hepatitis, Alcoholic/complications , Hepatitis, Alcoholic/diagnosis , Hepatitis, Alcoholic/drug therapy , Hepatitis, Alcoholic/mortality , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/etiology , Male , Outcome and Process Assessment, Health Care , Prednisone/administration & dosage , Prednisone/adverse effects , Renal Insufficiency/diagnosis , Renal Insufficiency/etiology , Survival Analysis , United States/epidemiology
17.
Clin Exp Pharmacol Physiol ; 47(2): 294-301, 2020 02.
Article in English | MEDLINE | ID: mdl-31631367

ABSTRACT

Recently both N-acetylcysteine (NAC) and Dexmedetomidine (DEX) have shown emerging roles in protection of acute lung injury (ALI). However, how their protective roles work and whether they can provide synergistic effects in ALI remain unknown. Here we explored it from the hot research viewpoint of Th1/Th2/Th17 cytokines balance. Lipopolysaccharide (LPS)-induced ALI was established and treated with NAC and/or DEX. Mice were divided into Sham group, ALI group, NAC group, DEX group and NAC+DEX group. Mice were sampled at 6, 12 and 24 hours after the model construction. Histopathology, wet to dry ratio and myeloperoxidase (MPO) activity were assessed in lung tissues. Protein concentration and cell count were assessed in bronchoalveolar lavage fluid (BALF). Th1/Th2/Th17 cytokines were assessed in plasma, BALF and lung homogenate. ALI-induced lung morphological damage, edema and aberrant MPO activity can be attenuated by NAC or DEX and mostly by NAC+DEX. NAC with DEX significantly reduced ALI-induced protein leakage and cell infiltration in BALF. Th1/Th2/Th17 cytokines imbalance aggravated with ALI progression. NAC, DEX and especially NAC+DEX can effectively correct these unbalanced cytokines. Galectin-9 and Tim-3 were transcriptionally up-regulated in ALI. Combination of NAC with DEX obtained a maximum effect on decreasing Galectin-9/Tim-3 expression. In summary, Th1/Th2/Th17 cytokines imbalance is newly found to participate in LPS-induced ALI. NAC or DEX administration can attenuate ALI by rebalancing Th1/Th2/Th17 cytokines. Their protective roles can be enhanced when co-administration, because DEX may relieve the Galectin-9/Tim-3 axis-mediated immune suppression.


Subject(s)
Acetylcysteine/administration & dosage , Acute Lung Injury/metabolism , Dexmedetomidine/administration & dosage , Th1 Cells/metabolism , Th17 Cells/metabolism , Th2 Cells/metabolism , Acute Lung Injury/chemically induced , Acute Lung Injury/prevention & control , Adrenergic alpha-2 Receptor Agonists/administration & dosage , Animals , Basic Helix-Loop-Helix Transcription Factors/antagonists & inhibitors , Basic Helix-Loop-Helix Transcription Factors/metabolism , Cytokines/antagonists & inhibitors , Cytokines/metabolism , Drug Synergism , Drug Therapy, Combination , Free Radical Scavengers/administration & dosage , Lipopolysaccharides/toxicity , Male , Mice , Mice, Inbred C57BL , Th1 Cells/drug effects , Th17 Cells/drug effects , Th2 Cells/drug effects
18.
BMC Pulm Med ; 20(1): 128, 2020 May 07.
Article in English | MEDLINE | ID: mdl-32380989

ABSTRACT

BACKGROUND: While antifibrotic drugs significantly decrease lung function decline in idiopathic pulmonary fibrosis (IPF), there is still an unmet need to halt disease progression. Antioxidative therapy with N-acetylcysteine (NAC) is considered a potential additional therapy that can be combined with antifibrotics in some patients in clinical practice. However, data on the efficacy, tolerability, and safety of this combination are scarce. We performed a systematic review and meta-analysis to appraise the safety, tolerability, and efficacy of the combination compared to treatment with pirfenidone alone. METHODS: We systematically reviewed all the published studies with combined pirfenidone (PFD) and NAC (PFD + NAC) treatment in IPF patients. The primary outcomes referred to decline in pulmonary function tests (PFTs) and the rates of IPF patients with side effects. RESULTS: In the meta-analysis, 6 studies with 319 total IPF patients were included. The PFD + NAC group was comparable to the PFD alone group in terms of the predicted forced vital capacity (FVC%) and predicted diffusion capacity for carbon monoxide (DLco%) from treatment start to week 24. Side effects and treatment discontinuation rates were also comparable in both groups. CONCLUSION: This systematic review and meta-analysis suggests that combination with NAC does not alter the efficacy, safety, or tolerability of PFD in comparison to PFD alone in IPF patients.


Subject(s)
Acetylcysteine/administration & dosage , Idiopathic Pulmonary Fibrosis/drug therapy , Pyridones/administration & dosage , Acetylcysteine/adverse effects , Administration, Inhalation , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Carbon Monoxide/blood , Drug Therapy, Combination , Free Radical Scavengers/administration & dosage , Humans , Idiopathic Pulmonary Fibrosis/physiopathology , Pyridones/adverse effects , Randomized Controlled Trials as Topic , Treatment Outcome , Vital Capacity/drug effects
19.
Drug Chem Toxicol ; 43(3): 234-239, 2020 May.
Article in English | MEDLINE | ID: mdl-29944001

ABSTRACT

Copper-nicotinate complex (CNC) has antioxidant activities through scavenging of free radicals formed inside the body. CNC also has anti-tumor and anti-inflammatory activities. The current study was designed to determine the effect of glycerol on rat kidney function and oxidative stress as well as, the potential nephroprotective effects of CNC. Forty male Wistar rats were randomly allocated into four equal groups. The groups of rats were as follows: GI was kept under normal control conditions; GII was orally given CNC at a dose of 0.043 mg kg-1 body weight (BW), three times/week for 4 weeks; GIII was administered glycerol (topical application) at a dose of 3.15 ml kg-1 BW daily for 4 weeks; and GIV was given CNC and glycerol with the same dose and route. The results revealed that CNC improves the renal dysfunctions induced by glycerol by recovering the levels of urea and creatinine to normal, as well as through the antioxidant status manifested by the normalization of catalase, superoxide dismutase, reduced glutathione, and malondialdehyde levels. Moreover, by its effect as an anti-oxidant, CNC reduces the effect of glycerol on the kidney by decreasing the fibrosis, degenerative changes and necrotic changes in the renal tubules. In conclusion, CNC could alleviate the side effects that might be caused by glycerol.


Subject(s)
Antioxidants/pharmacology , Copper/pharmacology , Kidney Diseases/prevention & control , Niacin/pharmacology , Animals , Antioxidants/administration & dosage , Catalase/metabolism , Copper/administration & dosage , Copper/chemistry , Creatinine/metabolism , Free Radical Scavengers/administration & dosage , Free Radical Scavengers/pharmacology , Glutathione/metabolism , Glycerol/toxicity , Male , Malondialdehyde/metabolism , Niacin/administration & dosage , Niacin/chemistry , Oxidative Stress/drug effects , Rats , Rats, Wistar , Superoxide Dismutase/metabolism , Urea/metabolism
20.
Int J Mol Sci ; 21(10)2020 May 21.
Article in English | MEDLINE | ID: mdl-32455532

ABSTRACT

Parkinson's disease (PD) is a chronic low-grade inflammatory process in which activated microglia generate cytotoxic factors-most prominently peroxynitrite-which induce the death and dysfunction of neighboring dopaminergic neurons. Dying neurons then release damage-associated molecular pattern proteins such as high mobility group box 1 which act on microglia via a range of receptors to amplify microglial activation. Since peroxynitrite is a key mediator in this process, it is proposed that nutraceutical measures which either suppress microglial production of peroxynitrite, or which promote the scavenging of peroxynitrite-derived oxidants, should have value for the prevention and control of PD. Peroxynitrite production can be quelled by suppressing activation of microglial NADPH oxidase-the source of its precursor superoxide-or by down-regulating the signaling pathways that promote microglial expression of inducible nitric oxide synthase (iNOS). Phycocyanobilin of spirulina, ferulic acid, long-chain omega-3 fatty acids, good vitamin D status, promotion of hydrogen sulfide production with taurine and N-acetylcysteine, caffeine, epigallocatechin-gallate, butyrogenic dietary fiber, and probiotics may have potential for blunting microglial iNOS induction. Scavenging of peroxynitrite-derived radicals may be amplified with supplemental zinc or inosine. Astaxanthin has potential for protecting the mitochondrial respiratory chain from peroxynitrite and environmental mitochondrial toxins. Healthful programs of nutraceutical supplementation may prove to be useful and feasible in the primary prevention or slow progression of pre-existing PD. Since damage to the mitochondria in dopaminergic neurons by environmental toxins is suspected to play a role in triggering the self-sustaining inflammation that drives PD pathogenesis, there is also reason to suspect that plant-based diets of modest protein content, and possibly a corn-rich diet high in spermidine, might provide protection from PD by boosting protective mitophagy and thereby aiding efficient mitochondrial function. Low-protein diets can also promote a more even response to levodopa therapy.


Subject(s)
Dietary Supplements , Free Radical Scavengers/therapeutic use , Parkinson Disease/prevention & control , Peroxynitrous Acid/metabolism , Plant Extracts/therapeutic use , Animals , Free Radical Scavengers/administration & dosage , Humans , Parkinson Disease/drug therapy , Parkinson Disease/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL